MeSH tree: D12.776.124.790.651.114.224.060.875
Modern breast cancer screening and treatment have transformed survival. Many women now live long and healthy lives after diagnosis, thanks to increasingly effective chemotherapy and targeted therapies: medicines designed ...
23 hours ago
0
16
The U.S. Food and Drug Administration has approved AstraZeneca's Enhertu (fam-trastuzumab deruxtecan-nxki) for both the neoadjuvant and adjuvant treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive ...
May 25, 2026
0
10
Patients with leptomeningeal metastasis (LM) have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and ...
Mar 18, 2026
0
10
Brazilian researchers have identified previously unknown forms of a protein linked to breast cancer. The discovery contributes to our understanding of variability in responses to treatment, even with the most advanced therapies.
Jan 20, 2026
0
11
The presence of circulating tumor DNA (ctDNA) in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer after they received neoadjuvant treatment and surgery predicted worse outcomes than in ...
Jan 14, 2026
0
12
Researchers at MIT and Stanford University have developed a new way to stimulate the immune system to attack tumor cells, using a strategy that could make cancer immunotherapy work for many more patients.
Dec 16, 2025
0
47
Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, potentially extending ...
Dec 10, 2025
0
16
The ABC Global Alliance today launched the Advanced Breast Cancer (ABC) Global Decade Report 2015–2025—a global assessment revealing a decade of remarkable scientific progress that has transformed ABC care for some patients ...
Nov 5, 2025
0
16
The U.S. Food and Drug Administration (FDA) announced Wednesday that it will relax certain rules for approving low-cost versions of some high-priced medications, in an effort to speed up access to cheaper alternatives.
Nov 1, 2025
0
41
In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with ...
Oct 20, 2025
0
14
